Skip to Content

Icon PLC ICLR

Morningstar Rating
$318.63 +2.24 (0.71%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Icon Continues to Benefit From Increased Clinical Trial Outsourcing Demand

We believe Icon possesses all the necessary elements to win share in the late-stage contract research organization market: global capabilities, full-service offerings, extensive regulatory and clinical expertise, investment in innovation and technology, and operational excellence. Icon is one of a handful of CROs with the global infrastructure to carry out late-stage, multinational trials and hone international regulatory expertise.

Price vs Fair Value

ICLR is trading at a 633% premium.
Price
$318.63
Fair Value
$123.00
Uncertainty
Medium
1-Star Price
$318.70
5-Star Price
$832.20
Economic Moat
Qzjstkn
Capital Allocation
Qgzndgzwk

Bulls Say, Bears Say

Bulls

Icon is highly exposed to the late-stage CRO industry, which due to its complexity is conducive to long-term competitive advantages.

Bears

Drawbacks to biotech funding or declines in outsourcing penetration rates could have a material impact on Icon's growth.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ICLR is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$316.39
Day Range
$314.81319.27
52-Week Range
$221.20344.77
Bid/Ask
$308.23 / $328.75
Market Cap
$26.38 Bil
Volume/Avg
435,076 / 503,180

Key Statistics

Price/Earnings (Normalized)
23.31
Price/Sales
3.21
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
41,150

Competitors

Valuation

Metric
ICLR
IQV
MEDP
Price/Earnings (Normalized)
23.3120.6741.08
Price/Book Value
2.796.1118.59
Price/Sales
3.212.626.53
Price/Cash Flow
19.7816.6036.12
Price/Earnings
ICLR
IQV
MEDP

Financial Strength

Metric
ICLR
IQV
MEDP
Quick Ratio
1.160.780.72
Current Ratio
1.210.880.78
Interest Coverage
3.373.00
Quick Ratio
ICLR
IQV
MEDP

Profitability

Metric
ICLR
IQV
MEDP
Return on Assets (Normalized)
4.85%7.28%21.26%
Return on Equity (Normalized)
9.19%31.85%67.47%
Return on Invested Capital (Normalized)
8.41%12.78%49.10%
Return on Assets
ICLR
IQV
MEDP
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
RbzxgjfvhGlhj$217.3 Bil
Danaher Corp
DHR
PgmbcvmrsLkcnlkf$190.7 Bil
IDEXX Laboratories Inc
IDXX
FsbnrccjwGtpsc$41.6 Bil
Agilent Technologies Inc
A
HvvtzxhvzCxdb$39.4 Bil
IQVIA Holdings Inc
IQV
MqqygpftZdnmxb$38.8 Bil
Mettler-Toledo International Inc
MTD
PvyylqlckjVgbpdv$31.6 Bil
Waters Corp
WAT
LwdrmprggxDdv$17.5 Bil
Labcorp Holdings Inc
LH
RscgvvpbRpdscv$17.4 Bil
Illumina Inc
ILMN
KgdljwdhFctktl$17.2 Bil

Sponsor Center